In a meta-analysis of trials evaluating cardiovascular outcomes with different GLP-1 receptor agonists, participants assigned to GLP-1 receptor agonists had a significant 11% lower risk of hospitalization for HF (136). This evidence concerns the gene GLP1R and hydrops fetalis.